Gene Therapy and Stem Cell Transplantation in Retinal Disease: The New Frontier

详细信息    查看全文

• 作者：Robert E. MacLaren ; DPhil ; FRCS¹ ; ² ; ^{enquiries@eye.ox.ac.uk" class="auth_mail" title="E-mail the corresponding author} ; Jean Bennett ; MD ; PhD³ ; Steven D. Schwartz ; MD⁴
• 关键词：AAV ; adeno-associated virus ; AAV2 ; adeno-associated viral vector serotype 2 ; AMD ; age-related macular degeneration ; iPSC ; induced pluripotent stem cell ; RP ; retinitis pigmentosa ; RPE ; retinal pigment epithelium ; VEGF ; vascular endothelial growth factor
• 刊名：Ophthalmology
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：123
• 期：10_supp_S
• 页码：S98-S106
• 全文大小：2170 K

文摘

Gene and cell therapies have the potential to prevent, halt, or reverse diseases of the retina in patients with currently incurable blinding conditions. Over the past 2 decades, major advances in our understanding of the pathobiologic basis of retinal diseases, coupled with growth of gene transfer and cell transplantation biotechnologies, have created optimism that previously blinding retinal conditions may be treatable. It is now possible to deliver cloned genes safely and stably to specific retinal cell types in humans. Preliminary results testing gene augmentation strategies in human recessive diseases suggest promising safety and efficacy profiles, including improved visual function outcomes over extended periods. Additional gene-based strategies under development include approaches to autosomal dominant disease (“gain of function”), attempts to deliver genes encoding therapeutic proteins with proven mechanisms of action interfering with specific disease pathways, and approaches that could be used to render retinal cells other than atrophied photoreceptors light sensitive. In the programs that are the furthest along—pivotal regulatory safety and efficacy trials studying individuals with retinal degeneration resulting from RPE65 mutations—initial results reveal a robust safety profile and clinically significant improvements in visual function, thereby making this program a frontrunner for the first approved gene therapy product in the United States. Similar to gene therapy, progress in regenerative or stem cell–based transplantation strategies has been substantial. It is now possible to deliver safely stem cell–derived, terminally differentiated, biologically and genetically defined retinal pigment epithelium (RPE) to the diseased human eye. Although demonstration of clinical efficacy is still well behind the gene therapy field, multiple programs investigating regenerative strategies in RPE disease are beginning to enroll subjects, and initial results suggest possible signs of efficacy. Stem cells capable of becoming other retinal cell types, such as photoreceptors, are on the cusp of clinical trials. Stem cell–derived transplants can be delivered to precise target locations in the eye, and their ability to ameliorate, reverse, regenerate, or neuroprotect against disease processes can be assessed. Results from these studies will provide foundational knowledge that may lead to clinically significant therapies for currently untreatable retinal disease.